Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,120 GBX | +4.67% | +8.21% | +64.71% |
Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Business Summary
Number of employees: 78
Sales per Business
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Synthetic DNA and RNA Products
92.5
%
| 0 | 95.0 % | 0 | 92.5 % | -22.74% |
Licences and Royalties
7.5
%
| 0 | 5.0 % | 0 | 7.5 % | +17.65% |
Sales per region
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
60.4
%
| 0 | 69.5 % | 0 | 60.4 % | -31.06% |
Europe
31.7
%
| 0 | 24.3 % | 0 | 31.7 % | +3.66% |
Rest of World
7.8
%
| 0 | 6.2 % | 0 | 7.8 % | 0.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 47 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Director/Board Member | 53 | - | |
Chairman | 68 | 20-12-21 | |
Heikki Lanckriet
CEO | Chief Executive Officer | 47 | 20-12-21 |
Director/Board Member | 55 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,805,208 | 3,893,037 ( 30.40 %) | 0 | 30.40 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+64.71% | 170M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- 4BB Stock
- Company 4basebio PLC